Ruthenium nitrosyl complexes are actively investigated as antitumor agents. Evaluation of potential interactions between cytochromes P450 (CYPs) with new compounds is carried out regularly during early drug development. In this study we have investigated the cytotoxic and antiproliferative activities of ruthenium nitrosyl complexes with methyl/ethyl esters of nicotinic and isonicotinic acids and γ-picoline against 2D and 3D cultures of human hepatocellular carcinoma HepG2 and non-cancer human lung fibroblasts MRC-5, assessed their photoinduced activity at λrad = 445 nm, and also evaluated their modulating effect on CYP3A4, CYP2C9, and CYP2C19. The study of cytotoxic and antiproliferative activities against 2D and 3D cell models was performed using phenotypic-based high content screening (HCS). The expression of CYP3A4, CYP2C9, and CYP2C19 mRNAs and CYP3A4 protein was examined using target-based HCS. The results of CYP3A4 mRNA expression were confirmed by real-time reverse transcription-polymerase chain reaction (RT-PCR). The ruthenium nitrosyl complexes exhibited a dose-dependent cytotoxic effect against HepG2 and MRC-5 cells. The cytotoxic activity of complexes with ethyl isonicotinate (1) and nicotinate (3, 4) was significantly lower for MRC-5 than for HepG2, for a complex with methyl isonicotinate (2) it was higher for MRC-5 than for HepG2, for a complex with γ-picoline (5) it was comparable for both lines. The antiproliferative effect of complexes 2 and 5 was one order of magnitude higher for MRC-5; for complexes 1, 3, and 4 it was comparable for both lines. The cytotoxic activity of all compounds for 3D HepG2 was lower than for 2D HepG2, with the exception of 4. Photoactivation affected the activity of complex 1 only. Its cytotoxic activity decreased, while the antiproliferative activity increased. The ruthenium nitrosyl complexes 1–4 acted as inducers of CYP3A4 and CYP2C19, while the complex with γ-picoline (5) induced of CYP3A4. Among the studied ruthenium nitrosyl complexes, the most promising potential antitumor compound is the ruthenium compound with methyl nicotinate (4).
Klyushova L.S., Vavilin V.A., Grishanova A.Yu. (2024) The cytotoxic and antiproliferative properties of ruthenium nitrosyl complexes and their modulation effect on cytochrome P450 in the HepG2 cell line. Biomeditsinskaya Khimiya, 70(1), 33-40.
Klyushova L.S. et al. The cytotoxic and antiproliferative properties of ruthenium nitrosyl complexes and their modulation effect on cytochrome P450 in the HepG2 cell line // Biomeditsinskaya Khimiya. - 2024. - V. 70. -N 1. - P. 33-40.
Klyushova L.S. et al., "The cytotoxic and antiproliferative properties of ruthenium nitrosyl complexes and their modulation effect on cytochrome P450 in the HepG2 cell line." Biomeditsinskaya Khimiya 70.1 (2024): 33-40.
Klyushova, L. S., Vavilin, V. A., Grishanova, A. Yu. (2024). The cytotoxic and antiproliferative properties of ruthenium nitrosyl complexes and their modulation effect on cytochrome P450 in the HepG2 cell line. Biomeditsinskaya Khimiya, 70(1), 33-40.
References
Gasser G., Ott I., Metzler-Nolte N. (2011) Organometallic anticancer compounds. J. Med. Chem., 54(1), 3-25. CrossRef Scholar google search
Zhang P., Sadler P.J. (2017) Advances in the design of organometallic anticancer complexes. J. Organomet. Chem., 839, 5-14. CrossRef Scholar google search
Singh V.K., Singh V.K., Mishra A., Varsha, Singh A.A., Prasad G., Singh A.K. (2023) Recent advancements in coordination compounds and their potential clinical application in the management of diseases: An up-to-date review. Polyhedron, 241, 116485. CrossRef Scholar google search
Tsvetkova D., Ivanova S. (2022) Application of approved cisplatin derivatives in combination therapy against different cancer diseases. Molecules, 27(8), 2466. CrossRef Scholar google search
Barabas K., Milner R., Lurie D., Adin C. (2008) Cisplatin: A review of toxicities and therapeutic applications. Veterinary Comparative Oncology, 6(1), 1-18. CrossRef Scholar google search
Sun Y., Lu Y., Bian M., Yang Z., Ma X., Liu W. (2021) Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment. Eur. J. Med. Chem., 211, 113098. CrossRef Scholar google search
Leijen S., Burgers S.A., Baas P., Pluim D., Tibben M., van Werkhoven E., Alessio E., Sava G., Beijnen J.H., Schellens J.H.M. (2015) Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Investigational New Drugs, 33(1), 201-214. CrossRef Scholar google search
Alessio E., Messori L. (2019) NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry. Molecules, 24(10), 1995. CrossRef Scholar google search
Stepanenko I., Zalibera M., Schaniel D., Telser J., Arion V.B. (2022) Ruthenium-nitrosyl complexes as NO-releasing molecules, potential anticancer drugs, and photoswitches based on linkage isomerism. Dalton Transactions, 51(14), 5367-5393. CrossRef Scholar google search
Ridnour L.A., Thomas D.D., Switzer C., Flores-Santana W., Isenberg J.S., Ambs S., Roberts D.D., Wink D.A. (2008) Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide — Biol. Chem., 19(2), 73-76. CrossRef Scholar google search
Bocé M., Tassé M., Mallet-Ladeira S., Pillet F., da Silva C., Vicendo P., Lacroix P.G., Malfant I., Rols M.-P. (2019) Effect of trans(NO, OH)-[RuFT(Cl)(OH)NO](PF6) ruthenium nitrosyl complex on methicillin-resistant Staphylococcus epidermidis. Sci. Rep., 9(1), 4867. CrossRef Scholar google search
Makhinya A.N., Eremina J.A., Sukhikh T.S., Baidina I.A., Il’in M.A., Klyushova L.S., Lider E.V. (2019) Cytotoxicity and crystal structures of nitrosoruthenium complexes mer-[Ru(NO)Py2Cl3] and mer-[Ru(NO)(γ-Pic)2Cl3]. ChemistrySelect, 4(19), 5866-5871. CrossRef Scholar google search
Rechitskaya E.D., Kuratieva N.V., Lider E.V., Eremina J.A., Klyushova L.S., Eltsov I.V., Kostin G.A. (2020) Tuning of cytotoxic activity by bio-mimetic ligands in ruthenium nitrosyl complexes. J. Mol. Struct., 1219, 128565. CrossRef Scholar google search
Choi J.M., Oh S.J., Lee S.Y., Im J.H., Oh J.M., Ryu C.S., Kwak H.C., Lee J.-Y., Kang K.W., Kim S.K. (2015) HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics. Arch. Pharm. Res., 38(5), 691-704. CrossRef Scholar google search
Nekvindova J., Mrkvicova A., Zubanova V., Hyrslova Vaculova A., Anzenbacher P., Soucek P., Radova L., Slaby O., Kiss I., Vondracek J., Spicakova A., Bohovicova L., Fabian P., Kala Z., Palicka V. (2020) Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. Biochem. Pharmacol., 177, 113912. CrossRef Scholar google search
Wang X., Yu T., Liao X., Yang C., Han C., Zhu G., Huang K., Yu L., Qin W., Su H., Liu X., Peng T. (2018) The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma. Cancer Medicine, 7(4), 966-980. CrossRef Scholar google search
Ashida R., Okamura Y., Ohshima K., Kakuda Y., Uesaka K., Sugiura T., Ito T., Yamamoto Y., Sugino T., Urakami K., Kusuhara M., Yamaguchi K. (2017) CYP3A4 gene is a novel biomarker for predicting a poor prognosis in hepatocellular carcinoma. Cancer Genomics Proteomics, 14(6), 445-453. CrossRef Scholar google search
Zanger U.M., Schwab M. (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther., 138(1), 103-141. CrossRef Scholar google search
Lu C., Di L. (2020) In vitro and in vivo methods to assess pharmacokinetic drug-drug interactions in drug discovery and development. Biopharmaceutics Drug Disposition, 41(1-2), 3-31. CrossRef Scholar google search
Solovieva A.O., Vorotnikov Y.A., Trifonova K.E., Efremova O.A., Krasilnikova A.A., Brylev K.A., Vorontsova E.V., Avrorov P.A., Shestopalova L.V., Poveshchenko A.F., Mironov Y.V., Shestopalov M.A. (2016) Cellular internalisation, bioimaging and dark and photodynamic cytotoxicity of silica nanoparticles doped by {Mo6I8}4+ metal clusters. J. Materials Chem. B, 4(28), 4839-4846. CrossRef Scholar google search
Sirenko O., Mitlo T., Hesley J., Luke S., Owens W., Cromwell E.F. (2015) High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures. Assay Drug Development Technologies, 13(7), 402-414. CrossRef Scholar google search
Mancio-Silva L., Fleming H.E., Miller A.B., Milstein S., Liebow A., Haslett P., Sepp-Lorenzino L., Bhatia S.N. (2019) Improving drug discovery by nucleic acid delivery in engineered human microlivers. Cell Metabolism, 29(3), 727-735. CrossRef Scholar google search
Mervin L.H., Cao Q., Barrett I.P., Firth M.A., Murray D., McWilliams L., Haddrick M., Wigglesworth M., Engkvist O., Bender A. (2016) Understanding cytotoxicity and cytostaticity in a high-throughput screening collection. ACS Chemical Biology, 11(11), 3007-3023. CrossRef Scholar google search
